{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:38Z","timestamp":1793946578297,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017958","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010849","name":"Wuhan Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105497","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:39:17Z","timestamp":1784561957000},"page":"105497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Molecular mechanisms of targeted therapy in breast cancer: An integrated signaling network perspective"],"prefix":"10.1016","volume":"226","author":[{"given":"Yadong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maona","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105497_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10555-013-9441-9","article-title":"Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review","volume":"32","author":"Azmi","year":"2013","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.critrevonc.2026.105497_bib4","article-title":"PROTAC technology: a new era for targeted protein degradation in cancer therapy","volume":"580","author":"Bai","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105497_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1)","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib9","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib10","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105497_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105497_bib12","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355)","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105497_bib13","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib14","first-page":"1073","article-title":"Trastuzumab deruxtecan (T-DXd) vs chemotherapy in HER2-low and HER2-ultralow metastatic breast cancer: DESTINY-Breast06","volume":"391","author":"Curigliano","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib16","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2\u2212 metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105497_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105497_bib19","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105497_bib21","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Garrett","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105497_bib22","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib23","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2026.105497_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105497_bib26","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic HR-positive breast cancer","volume":"15","author":"Hamilton","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2026.105497_bib28","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105497_bib29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105497_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105497_bib34","article-title":"Inavolisib plus palbociclib and fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer: INAVO120 phase III results","volume":"35","author":"Jhaveri","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel versus placebo plus nab-paclitaxel as first-line treatment for metastatic or recurrent triple-negative breast cancer (TORCHLIGHT)","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib36","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2007.11.002","article-title":"Tamoxifen: catalyst for the change to targeted therapy","volume":"44","author":"Jordan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105497_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105497_bib39","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1128\/MCB.00941-08","article-title":"MicroRNA-155 is regulated by the transforming growth factor \u03b2\/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA","volume":"28","author":"Kong","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.critrevonc.2026.105497_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12943-020-01259-6","article-title":"Circular HER2 RNA positive triple-negative breast cancer is sensitive to pertuzumab","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105497_bib42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib43","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105497_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105497_bib45","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2015.00024","article-title":"PTEN: multiple functions in human malignant tumors","volume":"5","author":"Milella","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib48","doi-asserted-by":"crossref","first-page":"29897","DOI":"10.1074\/jbc.M804612200","article-title":"MicroRNA-221\/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1","volume":"283","author":"Miller","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105497_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105497_bib53","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105497_bib54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105497_bib55","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-17-1229","article-title":"Discovery of selective estrogen receptor covalent antagonists for the treatment of ER\u03b1^WT^ and ER\u03b1^MUT^ breast cancer","volume":"8","author":"Puyang","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105497_bib56","first-page":"111","article-title":"MicroRNA-154 inhibits breast cancer cell proliferation and invasion by targeting ADAM9","volume":"53","author":"Qin","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib57","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1038\/sj.onc.1206004","article-title":"Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells","volume":"21","author":"Real","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105497_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.critrevonc.2026.105497_bib59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib60","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib61","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: SOPHIA trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105497_bib64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105497_bib65","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ymthe.2019.05.011","article-title":"circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p\/FOXO3a axis in breast cancer","volume":"27","author":"Sang","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105497_bib66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105497_bib67","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib68","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105497_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2026.105497_bib71","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib72","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib73","first-page":"3550","article-title":"ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor","volume":"14","author":"Soltoff","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105497_bib75","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105497_bib76","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105497_bib78","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib79","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib80","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib81","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105497_bib82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105497_bib83","first-page":"703","article-title":"miR-21 confers trastuzumab resistance by targeting LZTFL1 in HER2-positive breast cancer","volume":"174","author":"Wang","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105497_bib84","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105497_bib85","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE)","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib86","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105497_bib87","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105497_bib88","first-page":"841","article-title":"Circular RNA c100395 suppresses breast cancer progression by modulating the miR-1228\/MAPK6 axis","volume":"27","author":"Yu","year":"2020","journal-title":"Breast Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:48:15Z","timestamp":1793944095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":88,"alternative-id":["S1040842826003847"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105497","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of targeted therapy in breast cancer: An integrated signaling network perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105497"}}